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This editorial refers to ‘Biodegradable-polymer drug-
eluting stents vs. bare metal stents vs. durable-polymer
drug-eluting stents: a systematic review and Bayesian ap-
proach network meta-analysis’†, by S.-H. Kang et al., on
page 1147
Polymers of drug-eluting coronary stents (DES) provide a stable
matrix for drugs to be diffused into the damaged vessel wall and
modulate drug release. They lose their function after all drug is
released; however, by disintegration, all durable polymers carry the
risk for local inflammation, neoatherosclerosis, and thrombosis. Al-
though polymers are not the only reason for this pathophysiological
cascade leading to late stent thrombosis (ST) with related cardiac
death andmyocardial infarction, it was obvious that new biocompat-
ible or totally bioabsorbable polymers should be developed. The
goals of such DES with biodegradable polymers (BP-DES) were
therefore to reduce the risk of late or very late ST with no increased
rateof target vessel revascularization comparedwith first-generation
DES, thereby limiting the duration of dual antiplatelet therapy
(DAPT) needed. In other words, BP-DES should be as effective as
durable polymer DES (DP-DES) and, beyond 1 year after implant-
ation, as safe as bare-metal stents (BMS).
Accordingly, BP-DES have been tested in several studies, showing
non-inferiority compared with first-generation DES regarding effi-
cacy and safety up to 9–12months.1,2 The firstmeta-analyses also in-
cluding initial comparisons with second-generation DES confirmed
these findings but pointed—perhaps surprisingly—to a higher rate
of ST for BP-DES within the first year after implantation.3 Results
on very late ST, i.e. beyond 1 year, remained limited, but follow-up
studies of patients enrolled in the pivotal trials were presented
with conflicting results. Onemajor problem of all these trials directly
comparing BP-DES with other DP-DES is the low rate of ST events,
particularly beyond1 year, providinguncertain resultswithwide con-
fidence intervals. Thus, a new meta-analysis should define the safety
of currently available BP-DES relative to all other stents regarding ST.
With the specific aims to determinewhether DES in fact generally
differ in the risk of ST compared with BMS, whether the risk of ST
beyond1 year differswith differentDP-DES, and how safe and effect-
ive BP-DES are compared with DP-DES and BMS, a multiple treat-
ment network meta-analysis using a Bayasian framework is now
presented by Kang et al.4 Based on an electronic search, 113 trials
with .90 000 patients treated with BMS, DP-DES, and BP-DES
were analysed for definite or probable ST within 1 year. The
results showed that all DES tested except for paclitaxel- and
zotarolimus-eluting DP-DES proved to be superior to BMS with
regard to definite or probable STwithin 1 year. In individual compar-
isons, cobalt–chromium everolimus-eluting stents (CC-EES) were
the safest stents regardless of timing of ST compared with BMS and
all other DES including BP-DES. BP-DES also showed lower rates
of ST compared with BMS, but not compared with CC-EES, mainly
due to an increased risk of early ST. In addition, all DES reduced
the need for repeat revascularization compared with BMS and all
showed comparable clinical performance. Further results suggested
that not only the biodegradability of the polymer but also the optimal
combination of stent alloy, design, strut thickness, and drug, all com-
bined, determine the safety of DES.
Kang et al. claim that their study is the most updated and compre-
hensive network meta-analysis comparing contemporary stents in-
cluding BP-DES, with a greater statistical power compared with
a meta-analysis with a similar design just published by Palmerini
et al.5 Still, it may be instructive to compare these two similar
studies regarding the primary endpoint of the Kang study, i.e. ST
(see Figure 1). If we concentrate on findings of BP-DES compared
with CC-EES (as the ‘gold standard’ of all second-generation
DP-DES6), then both analyses found that ‘definite’ ST within the
first year occurred significantly more frequently with the newer
BP-DES than with CC-EES. This was also true for the more compre-
hensivedefinition of ‘definite or probable’ ST based on the findings of
Kang et al.4 but no longer according to Palmerini et al.5 Interestingly,
such a difference between ‘definite’ and ‘definite or probable’ STwas
also found beyond 1 year in both analyses: CC-EES were superior to
BP-DES beyond 1 year for ‘definite’ but not for ‘definite or probable’
ST. However, both groups of investigators stressed the limited com-
parative long-termdatawithBP-DES. In fact, no studywithBP-DES so
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far published had a primary endpoint at 2 years or later. Accordingly,
no significant differences between these two stents were found for
very late ST assessed by landmark analyses. Also, no direct compar-
isonsof BP-DESwithBMS, presumed tobe the ‘standard’ for lowvery
late ST risk, have been reported. The differences between these two
meta-analyses seem small, but are relevant and may be due to meth-
odological differences, to differences in definitions, or to limitations
of the meta-analyses themselves: these meta-analyses assume that
patients included in the different studies could have come from one
single studywhichwasobviouslynot trueeven if in sensitivity analyses
data of specific subgroups were excluded. In addition, meta-analyses
assume that similar comparisons in different trials have a consistent
risk–benefit ratio which may not be true either: just think of the dif-
ferent DAPT regimes used in the various trials, treatments to reduce
ST, the primary outcome of interest, or the known influence of man-
datory follow-up angiographies on event rates in some pivotal
studies. Thus, meta-analyses remain important to put low rate
events into a broader perspective but they have to be interpreted
with caution due to inherent limitations. In addition, one may ques-
tion the clinical relevance of differences which become significant
with .90 000 patients only.
Therefore, one has to look at individual stent comparisons again.
Forevents occurring beyond1 year, the LEADERS investigators care-
fully followed their patients up to 5 years and, in fact, found lower
rates of very late ‘definite’ ST of BP-DES compared with the first-
generation sirolimus-eluting DP-DES.7 These findings were con-
firmed recently when results were combined with 4-year follow-up
results of two ISAR studies.8 However, these analyses compared
Figure 1 Comparison (odds ratios and 95% confidence intervals) of cobalt–chromium everolimus-eluting stents (CC-EES) vs. biodegradable
polymer drug-eluting stents (BP-DES) for definite stent thrombosis (ST), definite or probable ST and myocardial infarction within and beyond
the first year in the two meta-analyses by Kang et al.4 and Palmerini et al.5 Note that there were no differences in death or cardiac death
between the two stents at any time in both studies. Arrows indicate ‘in favour of the stent’ they are pointing to; asterisks indicate that findings
(* ¼ difference; ** ¼ no difference) were described without corresponding odds ratios presented.
Editorial 1099
BP-DES with the first-generation sirolimus-DP-DES—which itself
has been shown to be associated with increased ST rates beyond 1
year—and not with the ‘gold-standard’ CC-EES. In fact, only one
study directly compared the DP-DES CC-EES with BP-EES, limited
to patients with acute myocardial infarction and a 1-year follow-up;9
with further follow-ups pending. In addition, it should be noted that
follow-up studies are secondary goals of randomized trials only,
unblinded, with information gathered by telephone contact or ques-
tionnaires rather than by rigid prospective examinations. To make
very late assessments even less asserting, two recent studies demon-
strated that progression of coronary disease becomes as relevant as
late stent-related problems 3–5 years after stent implantation10,11
when these late follow-ups are performed.
Additional problemswith follow-up studies focusing on STmay lie
in the difficulty in detecting ‘true’ ‘definite’, ‘probable’, or even ‘pos-
sible’ ST. Only carefully performed prospective evaluations including
autopsies in all patients who die and acute angiographies in all infarc-
tion patients could ensure that ‘true’ ST events are not missed. Only
on the basis of such meticulous late investigations was it possible to
describe the patho-anatomy of very late ST. Note that a cancer
death may also be due to coronary ST in view of the prothrombotic
state associated with certain cancers. Thus, .50% of ‘possible’ ST
weremost likely to be due to true ST based on a detailed retrospect-
ive analysis.12 Note also that risk differences in ST among different
DES are associated with different rates of death and myocardial in-
farction. Therefore, it is important to report ST not just alone but
also in the context of these events which are most important to
patients. In fact, it is of interest that both meta-analyses found no sig-
nificant differences in death or myocardial infarction between
BP-DES andCC-EES, an unexplained but clinically important discrep-
ancy compared with single ST results!
Thus, the findings of Kang et al. put the current trial results of
BP-DES in perspective with the available data of DP-DES and BMS
with regard to ST. The results also show that more long-term data
comparing BP-DES with DP-DES, particularly CC-EES, are needed,
as well as very late comparisons with BMS, the ‘standard’ for low
rates of very late ST. If polymer degradation was found to be the
reason for the increased 1-year ST rates of BP-DES noted, then
this could become a ‘killer’ argument for current BP-DES. The
effect of different DAPT regimes on these outcomes and the effect
of stent outcomes on the need for prolonged DAPT will have to
be defined. Other aspects as highlighted by Kang et al., such as
stent design and drug load, will also be important. Corresponding
studies with newer BP-DES are running or planned, such as with
the ORSIRO
TM
stent (Biotronik, Germany), the SYNERGY
TM
stent
(Boston Scientific, USA), and others13–15 as presented at the Trans-
catheter Cardiovascular Therapeutics Meetings in 2013. However,
this situation will continue—calling for the patience of researchers,
physicians, patients, and industry—until a more final assessment of
BP-DES is possible! Follow-ups of at least 2 years and a large
number of patients or multiple studies are needed to ascertain
whether BP-DES really improve late outcomes by enhancing
healing and getting rid of thrombogenic polymer materials such
that DAPT duration may be shortened.
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